Total Funding
81
62
Total FundingPost-IPO Equity raised
Growth Score
10 pts
Heat Score
-20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
39664
Nektar Therapeutics develops therapeutics based on its advanced polymer conjugate chemistry technology platform.
Acquired by 
Ampersand Capital Partners
- Jillian B. Thomsen: SVP Finance & Chief Accounting Officer
- Jillian B. Thomsen: Senior Vice President & Chief Financial Officer
About the Company
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
